Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 5 studies | 47% ± 25% | |
endothelial cell | 3 studies | 16% ± 1% |
Insufficient scRNA-seq data for expression of CYP2A6 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 40904.56 | 226 / 226 | 87% | 753.13 | 355 / 406 |
breast | 99% | 64.45 | 453 / 459 | 34% | 88.08 | 380 / 1118 |
lung | 95% | 58.16 | 548 / 578 | 17% | 4.40 | 198 / 1155 |
brain | 88% | 14.01 | 2336 / 2642 | 23% | 0.47 | 165 / 705 |
uterus | 99% | 61.91 | 168 / 170 | 12% | 0.69 | 56 / 459 |
prostate | 97% | 30.59 | 237 / 245 | 13% | 0.23 | 63 / 502 |
ovary | 99% | 78.80 | 179 / 180 | 9% | 0.23 | 40 / 430 |
adrenal gland | 95% | 38.30 | 246 / 258 | 13% | 0.52 | 30 / 230 |
bladder | 95% | 34.81 | 20 / 21 | 7% | 0.34 | 36 / 504 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.22 | 1 / 1 |
adipose | 96% | 39.52 | 1156 / 1204 | 0% | 0 | 0 / 0 |
intestine | 78% | 13.41 | 756 / 966 | 2% | 1.09 | 12 / 527 |
esophagus | 63% | 8.00 | 908 / 1445 | 15% | 1.30 | 28 / 183 |
muscle | 76% | 9.67 | 614 / 803 | 0% | 0 | 0 / 0 |
thymus | 74% | 10.18 | 484 / 653 | 1% | 0.02 | 6 / 605 |
skin | 72% | 10.88 | 1297 / 1809 | 3% | 0.06 | 12 / 472 |
blood vessel | 70% | 10.04 | 937 / 1335 | 0% | 0 | 0 / 0 |
spleen | 65% | 20.54 | 157 / 241 | 0% | 0 | 0 / 0 |
stomach | 50% | 5.04 | 180 / 359 | 8% | 0.24 | 22 / 286 |
pancreas | 40% | 3.88 | 131 / 328 | 9% | 0.19 | 16 / 178 |
heart | 48% | 5.14 | 415 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 36% | 5.28 | 336 / 929 | 0% | 0 | 0 / 0 |
kidney | 24% | 2.06 | 21 / 89 | 2% | 1.10 | 15 / 901 |
tonsil | 0% | 0 | 0 / 0 | 4% | 0.64 | 2 / 45 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.05 | 1 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0019373 | Biological process | epoxygenase P450 pathway |
GO_0042178 | Biological process | xenobiotic catabolic process |
GO_0046226 | Biological process | coumarin catabolic process |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0008202 | Biological process | steroid metabolic process |
GO_0009804 | Biological process | coumarin metabolic process |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005737 | Cellular component | cytoplasm |
GO_0005881 | Cellular component | cytoplasmic microtubule |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0019899 | Molecular function | enzyme binding |
GO_0008389 | Molecular function | coumarin 7-hydroxylase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0008392 | Molecular function | arachidonic acid epoxygenase activity |
GO_0020037 | Molecular function | heme binding |
GO_0016712 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen |
Gene name | CYP2A6 |
Protein name | Cytochrome P450 family 2 subfamily A member 6 Cytochrome P450 2A6 (EC 1.14.14.-) (1,4-cineole 2-exo-monooxygenase) (CYPIIA6) (Coumarin 7-hydroxylase) (Cytochrome P450 IIA3) (Cytochrome P450(I)) |
Synonyms | CYP2A3 |
Description | FUNCTION: Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity. . |
Accessions | P11509 ENST00000600495.1 ENST00000301141.10 M0R2Z4 |